-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
-
A 52-year-old woman had systemic symptoms including nausea and vomiting. Seven months prior to admission she had a subarachnoid hemorrhage and needed multiple ventriculo-pleural shunts.
-
Raltegravir (RAL) received FDA approval in 2007 and is now used in treatment of both treatment-experienced and treatment-naïve patients.
-
A previously healthy 51-year-old man with no history of travel outside of Montana presented to a local emergency department in May 2009 with fever, frontal headache, dizziness, numbness, and tingling.
-
A randomized, double-blind, placebo-controlled trial of immediate vs. deferred ART in 253 patients with HIV-associated TB meningitis was conducted to determine whether immediate ART reduced the risk of death.
-
The numbers of households with pets are increasing in many countries across the world. In addition, data obtained from media sources note a trend in the percentage of these pets sleeping in, or on, the owner's bed.
-
The Vermont MDRO Prevention Collaborative administered a baseline infection prevention survey developed by the CDC to assess the status of long term care facilities as the project began.
-
The challenge of improving infection prevention is a formidable one, given such basic conundrums as how do you effectively isolate an infected or colonized resident who needs to move about and socialize for their overall health and well-being?
-
Fifteen percent of U.S. nursing homes receive deficiency citations for infection control per year, with many of those breaches tied to staffing issues, long term care researchers report.
